With this extension, IXCHIQ ® , the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“ Valneva ” or the “ Company ”), a specialty vaccine company, today announces that it has filed a prospectus supplement as part of the renewal of its ...

The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.

Valneva also has an ongoing license agreement with the Serum Institute of India (SII) to supply its vaccine at an affordable ...

Saint-Herblain (France), March 20, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its consolidated financial results for the year ended ...

Saint-Herblain (France), March 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 24, 2025, of its 2024 Universal ...

Valneva SE, a specialty vaccine company, announced that it is responding to the chikungunya outbreak that is rapidly intensifying in France’s Island of La Réunion with its vaccine Ixchiq. In agreement ...

Saint-Herblain (France), March 26, 2025 – Valneva SE (Nasdaq ... provide an update after each capital increase on a dedicated location on its corporate website in order to inform investors ...

Saint-Herblain (France), March 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces that it has filed a ...